Description
Product Usage Information
Western Blotting: 1:1000
Simple Western™: 1:50 - 1:250
Immunoprecipitation: 1:200
Chromatin IP: 1:50
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. For a carrier free (BSA and azide free) version of this product see product # 23164 .
Protocol
Available protocols: Western Blotting, Immunoprecipitation, Chromatin IP
Specificity / Sensitivity
Androgen Receptor (AR-V7 Specific) (E3O8L) Rabbit Monoclonal Antibody recognizes endogenous levels of total AR-V7 protein. This antibody does not cross-react with full-length AR protein, but immunoprecipitates a 120 kDa protein of unknown identity.
Species Reactivity: Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu639 of human androgen receptor (V7 isoform) protein.
Background
Androgen receptor (AR), a zinc finger transcription factor belonging to the nuclear receptor superfamily, is activated by phosphorylation and dimerization upon ligand binding (1). This promotes nuclear localization and binding of AR to androgen response elements in androgen target genes. Research studies have shown that AR plays a crucial role in several stages of male development and the progression of prostate cancer (2,3). The AR3 or AR-V7 isoform, which lacks the typical ligand binding domain, is created through the alternative splicing of cryptic exons (4-5). AR-V7 is frequently expressed in castration-resistant prostate cancer (CRPC) and while dependent on the activity of the full-length androgen receptor (AR-FL), AR-V7 can activate a completely distinct transcriptional program (6-8). While enzalutamide and abiraterone have been beneficial in treating CRPC through the ligand binding domain of AR-FL, resistance in patients has been shown to be associated with AR-V7 detection in circulating tumor cells (9-12). Studies probing into mechanisms of overcoming this resistance are currently being explored and may help in stratifying patient populations for more personalized therapies (13-15).
Alternate Names
AIS; ANDR; Androgen receptor; Androgen receptor splice variant 3; AR; AR iso3; AR-V7; AR8; DHTR; Dihydrotestosterone receptor; HUMARA; HYSP1; KD; NR3C4; Nuclear receptor subfamily 3 group C member 4; SBMA; SMAX1; TFM
